첫 페이지 News 본문

In the fourth quarter, Lilly's revenue was $9.35 billion, exceeding market expectations of $8.96 billion, with a year-on-year increase of 28%. Lilly's GLP-1 drug Zepbound is expected to dominate the weight loss market in 2024. However, Lilly faced limited production capacity in 2023 and took measures to increase supply in 2024.
CandyLake.com is an information publishing platform and only provides information storage space services.
Disclaimer: The views expressed in this article are those of the author only, this article does not represent the position of CandyLake.com, and does not constitute advice, please treat with caution.
您需要登录后才可以回帖 登录 | Sign Up

本版积分规则

123458026 新手上路
  • Follow

    0

  • Following

    0

  • Articles

    4